Lactic Acid Bacterial Composition for Allergic Rhinitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic rhinitis are inadequate in modulating immune cell differentiation and reducing pro-inflammatory cytokine secretion, leading to persistent symptoms and reduced quality of life.
Innovation Solution
A lactic acid bacterial composition comprising Limosilactobacillus reuteri GL-104 and Lacticaseibacillus rhamnosus F-1 strains, which reduces pro-inflammatory cytokine CXCL10 secretion and promotes macrophage polarization from M1 to M2 phenotype, thereby alleviating allergic rhinitis symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for allergic rhinitis, then symptoms can be managed temporarily, but immune cell differentiation is not effectively modulated and pro-inflammatory cytokine secretion persists
Solution Approach 1:
The patent changes the functional parameters of the probiotic formulation by specifying precise strain identifiers (Limosilactobacillus reuteri GL-104 and Lacticaseibacillus rhamnosus F-1) and their operational characteristics (viable strain, specific CFU counts ranging from 10^6 to 10^9 per day). This targeted parameter specification enables effective modulation of immune cell differentiation and reduction of pro-inflammatory cytokine secretion, resolving the contradiction between temporary symptom management and sustained immune modulation.
Solution Approach 2:
The patent employs a composite probiotic formulation combining two specific bacterial strains (Limosilactobacillus reuteri GL-104 and Lacticaseibacillus rhamnosus F-1) working synergistically. This composite approach enhances the ability to modulate immune cell differentiation and reduce CXCL10 secretion more effectively than single-strain preparations, addressing the limitation of conventional single-component treatments.
2Reliability
If probiotics are used to modulate immune system, then allergic response can be reduced, but safety and suitability for long-term use must be ensured
Solution Approach 1:
The patent employs food-acceptable excipients and conventional probiotic strains that are inherently safe for long-term consumption. The formulation uses established probiotic organisms (Limosilactobacillus reuteri and Lacticaseibacillus rhamnosus) with extensive safety records, eliminating concerns about harmful effects from long-term use while maintaining effective immune modulation.
Solution Approach 2:
The patent specifies precise operational parameters including viable strain identification, controlled CFU counts (10^6 to 10^9 per day), and food-acceptable excipient selection. These parameter controls ensure the probiotic formulation maintains safety and suitability for long-term use while effectively modulating the immune system, resolving the contradiction between immune modulation capability and long-term safety.
3Strength
If M1 macrophage polarization is promoted to fight infection, then immune response increases, but inflammatory symptoms in allergic rhinitis worsen
Solution Approach 1:
The patent changes the polarization state parameter of macrophages from M1 to M2 phenotype through the action of specific probiotic strains. This parameter transformation shifts the immune response from pro-inflammatory (M1) to anti-inflammatory (M2), thereby reducing inflammatory symptoms in allergic rhinitis while maintaining appropriate immune defense capabilities.
Solution Approach 2:
The patent converts the potentially harmful M1 macrophage polarization (which causes excessive inflammation) into beneficial M2 macrophage polarization (which promotes tissue repair and reduces inflammation). The probiotic strains facilitate this transformation, turning the harmful inflammatory response into a beneficial anti-inflammatory response that alleviates allergic rhinitis symptoms.
Data Source
AI summary
A lactic acid bacterial composition for modulating immune cell differentiation and/or reducing pro-inflammatory cytokine secretion includes: (a) a Limosilactobacillus reuteri GL-104 strain; and (b) a Lacticaseibacillus rhamnosus F-1 strain; wherein the GL-104 strain is deposited at the China Center for Type Culture Collection with a deposition number CCTCC M209138, and the F-1 strain is deposited at the China Center for Type Culture Collection with a deposition number CCTCC M2011124. Additionally, a method for treating or preventing allergic rhinitis by administering the foregoing composition to a subject in need thereof is also provided.